We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 546

Ninth Circuit okays pharma waste disposal ordinance
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

The Ninth Circuit Court of Appeals has upheld the validity of an Alameda County ordinance that requires prescription drug producers that sell brand


Fractured Myriad Genetics ruling follows SCOTUS remand
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

Ruling that one plaintiff had standing to seek a declaratory judgment as to the patent eligibility of certain genetic discoveries, the Federal Circuit Court of Appeals has once again reversed in part and affirmed in part a lower court’s determination that isolated DNA molecules and methods of comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible


Federal Circuit addresses personal jurisdiction in patent infringement litigation
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

Finding that the U.S. Supreme Court “has yet to reach a consensus on the proper articulation of the stream-of-commerce theory” of personal jurisdiction to assess whether a court has jurisdiction over a non-resident defendant in a patent infringement suit, the Federal Circuit Court of Appeals has applied its own theory, which assesses the pleadings and evidence under “any articulation of the stream-of-commerce theory,” and has determined that a district court in Wyoming properly dismissed two patent infringement lawsuits for lack of jurisdiction


Third Circuit refuses to stay effect of anti-competitive ruling in pay-for-delay case
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

The Third Circuit Court of Appeals has denied a request that it stay the mandate of its July 2012 ruling that “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade.”


Biotech employment gains make up for pharma losses
  • Shook Hardy & Bacon LLP
  • USA
  • June 26 2014

According to new EP Vantage research, while employment in those companies characterized as "Big Pharma" decreased slightly in the period 2003-2013


Genetic screening company secures $28 million to expand product line and market tests
  • Shook Hardy & Bacon LLP
  • USA
  • May 22 2014

A Silicon Valley startup company that focuses on screening prospective parents for more than 100 rare inherited diseases has reportedly raised $28


India to ban PET packaging for certain pharmaceuticals
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of


Patent reforms targeting abusive litigation remain stalled in Senate
  • Shook Hardy & Bacon LLP
  • USA
  • May 22 2014

A coalition of companies, trade associations and startups concerned about delays in the U.S. Senate in enacting patent law reforms to address


FDA warns Japan-based medical equipment maker on quality controls
  • Shook Hardy & Bacon LLP
  • USA
  • October 17 2013

The U.S. Food and Drug Administration (FDA) recently issued a warning letter to a Japan-based company that makes Class I and II non-sterile laser


D.C. Circuit upholds civil conviction in manufacture of stem cell therapy
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

The D.C. Circuit Court of Appeals has affirmed a lower court's grant of the government's motion for summary judgment and the imposition of a